{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:48:37Z","timestamp":1785786517192,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-leucine-rich glioma-inactivated 1 encephalitis is a newly emerged entity characterized by frequent faciobrachial dystonic seizures and a wide spectrum of subacute clinical symptoms such as other seizure types, mood and behavioral changes, and memory loss. We should be aware of differentiating this diagnosis from psychogenic nonepileptic seizures. Mesial temporal, limbic structures, and basal ganglia are the most commonly involved regions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>Here we review the available data, and report on two young Iranian (White) females, 24 and 18\u00a0years old, who represent distinct aspects of the disease. The clinical presentation and degree of tissue involvement varies to some extent in the two reported cases. Case 1 had prominent neuropsychiatric symptoms and suffered from frequent faciobrachial dystonic seizures with more significant basal ganglia involvement, whereas case 2 suffered from severe memory decline and dialeptic seizures along with mesial temporal involvement. Symptoms were refractory to usual treatment and prompt immunotherapy was needed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This disease has a rather favorable outcome provided that treatment is initiated early. However, resistance to first-line treatment, relapses, and long-term complications highlight the need to establish reliable biomarkers to distinguish different subtypes of this disorder to predict the clinical outcome and prognosis, and to refine management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-022-03650-x","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T01:02:39Z","timestamp":1667955759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and\u00a0a review of the literature"],"prefix":"10.1186","volume":"16","author":[{"given":"Sanaz Ahmadi","family":"Karvigh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6159-2279","authenticated-orcid":false,"given":"Saeideh","family":"Salehizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahimeh","family":"Vahabizad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"3650_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2016-217083","author":"D Dash","year":"2016","unstructured":"Dash D, Tripathi M, Ihtisham K, Tripathi M. LGI1 encephalitis: a disease of jerks and confusion. BMJ Case Rep. 2016. https:\/\/doi.org\/10.1136\/bcr-2016-217083.","journal-title":"BMJ Case Rep"},{"key":"3650_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21767\/2171-6625.1000137","volume":"7","author":"K Bhardwaj","year":"2016","unstructured":"Bhardwaj K, Sharma SK, Pandey AK, et\u00a0al. A case of limbic encephalitis: antibody LGI1 associated encephalitis. J Neurol Neurosci. 2016;7:4. https:\/\/doi.org\/10.21767\/2171-6625.1000137.","journal-title":"J Neurol Neurosci"},{"key":"3650_CR3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003173","author":"A Sonderen","year":"2016","unstructured":"Sonderen A, Rolandm DT, Elias C, Lize C, et\u00a0al. Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology. 2016. https:\/\/doi.org\/10.1212\/WNL.0000000000003173.","journal-title":"Neurology"},{"issue":"12","key":"3650_CR4","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1586\/14737175.2015.1115720","volume":"15","author":"N Margherita","year":"2015","unstructured":"Margherita N, Shekeeb SM, Sudarshini R, Fabienne B, Russell CD. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother. 2015;15(12):1391\u2013419. https:\/\/doi.org\/10.1586\/14737175.2015.1115720.","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"3650_CR5","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1093\/brain\/awq213","volume":"133","author":"R Sarosh","year":"2010","unstructured":"Sarosh R, Sian A, Waters P, Kleopas A, Philippa P, et\u00a0al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan\u2019s syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734\u201348. https:\/\/doi.org\/10.1093\/brain\/awq213.","journal-title":"Brain"},{"key":"3650_CR6","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.autrev.2016.07.018","volume":"15","author":"AV Sonderen","year":"2016","unstructured":"Sonderen AV, Schreurs MWJ, Wirtz PW, SillevisSmitt PAE, Titulaer MJ. From VGKC to LGI1 and Caspr2 encephalitis: the evolution of a disease entity over time. Autoimmunity Rev. 2016;15:970\u20134. https:\/\/doi.org\/10.1016\/j.autrev.2016.07.018.","journal-title":"Autoimmunity Rev"},{"key":"3650_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000161","author":"EP Flanagan","year":"2015","unstructured":"Flanagan EP, Kotsenas AL, et\u00a0al. Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Am Acad Neurol. 2015. https:\/\/doi.org\/10.1212\/NXI.0000000000000161.","journal-title":"Am Acad Neurol"},{"key":"3650_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2020.07.021","author":"WP Liu","year":"2020","unstructured":"Liu WP, Wang M, Zhang C, Zhao CW, et\u00a0al. Application of the APE2 and RITE2 scores for autoimmune epilepsy in Chinese patients: a retrospective study. Res Sq. 2020. https:\/\/doi.org\/10.1016\/j.seizure.2020.07.021.","journal-title":"Res Sq"},{"key":"3650_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.05.048","author":"M Szots","year":"2014","unstructured":"Szots M, et\u00a0al. Natural course of LGI1 encephalitis: 3\u20135 years of follow-up without immunotherapy. J Neurol Sci. 2014. https:\/\/doi.org\/10.1016\/j.jns.2014.05.048.","journal-title":"J Neurol Sci"},{"issue":"1","key":"3650_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ana.24979","volume":"82","author":"A Gadoth","year":"2017","unstructured":"Gadoth A, Pittock SJ, Dubey D, Andrew McKeon A, Britto JW, et\u00a0al. Expanded phenotypes and outcomes among 256 LGI1\/CASPR2-IgG-positive patients. Ann Neurol. 2017;82(1):79\u201392. https:\/\/doi.org\/10.1002\/ana.24979.","journal-title":"Ann Neurol"},{"key":"3650_CR11","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.autrev.2016.07.018","volume":"15","author":"AV Sonderen","year":"2016","unstructured":"Sonderen AV, Schreurs MWJ, Sillevis PAE. From VGKC to LGI1 and Caspr2 encephalitis: the evolution of a disease entity over time. Autoimmun Rev. 2016;15:970\u20134. https:\/\/doi.org\/10.1016\/j.autrev.2016.07.018.","journal-title":"Autoimmun Rev"},{"key":"3650_CR12","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/brain\/aww012","volume":"139","author":"V Navarro","year":"2016","unstructured":"Navarro V, Kas A, Apartis E, Chami L, et\u00a0al. Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain. 2016;139:1079\u201393. https:\/\/doi.org\/10.1093\/brain\/aww012.","journal-title":"Brain"},{"key":"3650_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.618109","author":"X Shao","year":"2021","unstructured":"Shao X, Fan S, Luo H, Wong TY, et\u00a0al. Brain magnetic resonance imaging characteristics of anti-leucine-rich glioma-inactivated 1 encephalitis and their clinical relevance: a single-center study in China. Front Neurol. 2021. https:\/\/doi.org\/10.3389\/fneur.2020.618109.","journal-title":"Front Neurol"},{"key":"3650_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ebcr.2017.06.001","volume":"8","author":"RS Iyer","year":"2017","unstructured":"Iyer RS, Ramakrishnan TC, Karunakaran, Shinto A, et\u00a0al. Faciobrachial dystonic seizures result from fronto\u2013temporo\u2013basalganglial network involvement. Epilepsy Behav Case Rep. 2017;8:47\u201350. https:\/\/doi.org\/10.1016\/j.ebcr.2017.06.001.","journal-title":"Epilepsy Behav Case Rep"},{"issue":"5","key":"3650_CR15","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ana.22307","volume":"69","author":"R Sarosh","year":"2011","unstructured":"Sarosh R, Andrew W, Bethan L, et\u00a0al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892\u2013900. https:\/\/doi.org\/10.1002\/ana.22307.","journal-title":"Ann Neurol"},{"issue":"10","key":"3650_CR16","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1093\/brain\/awt212","volume":"136","author":"R Sarosh","year":"2013","unstructured":"Sarosh R, Charlotte J, Stagg J. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain. 2013;136(10):3151\u201362. https:\/\/doi.org\/10.1093\/brain\/awt212.","journal-title":"Brain"},{"issue":"8","key":"3650_CR17","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S1474-4422(10)70137-X","volume":"9","author":"M Lai","year":"2010","unstructured":"Lai M, Huijbers M, Lancaster E, Graus F, Gordon RB, et\u00a0al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776\u201385. https:\/\/doi.org\/10.1016\/S1474-4422(10)70137-X.","journal-title":"Lancet Neurol"},{"issue":"5","key":"3650_CR18","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrneurol.2017.43","volume":"13","author":"AV Sonderen","year":"2017","unstructured":"Sonderen AV, Petit-Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol. 2017;13(5):290\u2013301. https:\/\/doi.org\/10.1038\/nrneurol.2017.43.","journal-title":"Nat Rev Neurol"},{"key":"3650_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617722347","author":"S Yong-Won","year":"2018","unstructured":"Yong-Won S, Soon-Tae L, Kyung-Il P, et\u00a0al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2018. https:\/\/doi.org\/10.1177\/1756285617722347.","journal-title":"Ther Adv Neurol Disord"},{"key":"3650_CR20","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/brain\/awx323","volume":"141","author":"J Thompson","year":"2018","unstructured":"Thompson J, Mian B, Andrew G. The importance of early immunotherapy I patients with faciobrachial dystonic seizures. Brain. 2018;141:348\u201356. https:\/\/doi.org\/10.1093\/brain\/awx323.","journal-title":"Brain"},{"key":"3650_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/jnnp-2017-315720","volume":"89","author":"S Binks","year":"2018","unstructured":"Binks S, Klein CJ, Waters P, et\u00a0al. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. Neurol Neurosurg Psychiatry. 2018;89:526\u201334. https:\/\/doi.org\/10.1136\/jnnp-2017-315720.","journal-title":"Neurol Neurosurg Psychiatry"},{"issue":"25","key":"3650_CR22","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.3760\/cma.j.cn112137-20200330-01001","volume":"100","author":"Y Zhonghua","year":"2020","unstructured":"Zhonghua Y, Xue Z. Clinical features and outcomes in relapsing and monophasic patients with anti-leucine-rich glioma-inactivated 1 encephalitis. Zhonghua Yi Xue Za Zhi. 2020;100(25):1947\u201351. https:\/\/doi.org\/10.3760\/cma.j.cn112137-20200330-01001.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"10","key":"3650_CR23","doi-asserted-by":"publisher","first-page":"CS133","DOI":"10.12659\/msm.882034","volume":"17","author":"A Brenner","year":"2011","unstructured":"Brenner A, Brenner B, Belyaeva I, et\u00a0al. Rituximab associated neutropenia: description of three cases and an insight into the underlying pathogenesis. Med Sci Monit. 2011;17(10):CS133\u20137. https:\/\/doi.org\/10.12659\/msm.882034.","journal-title":"Med Sci Monit"},{"issue":"3","key":"3650_CR24","first-page":"175","volume":"37","author":"M Marvin","year":"2012","unstructured":"Marvin M. Multiple sclerosis review. Pharm Ther. 2012;37(3):175\u201384.","journal-title":"Pharm Ther"},{"key":"3650_CR25","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/archneur.62.2.258","volume":"62","author":"NL Monson","year":"2005","unstructured":"Monson NL, Cravens P, Frohman M, et\u00a0al. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol. 2005;62:258\u201364. https:\/\/doi.org\/10.1001\/archneur.62.2.258.","journal-title":"Arch Neurol"},{"key":"3650_CR26","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1212\/WNL.0000000000007475","volume":"92","author":"AAM Marienke","year":"2019","unstructured":"Marienke AAM, Marleen H, Rob PW, Rinze F, Maarten J. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology. 2019;92:2185\u201396. https:\/\/doi.org\/10.1212\/WNL.0000000000007475.","journal-title":"Neurology"},{"issue":"1","key":"3650_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1528-1157.1994.tb02930.x","volume":"35","author":"T Amelsvoort","year":"1994","unstructured":"Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia. 1994;35(1):181\u20138. https:\/\/doi.org\/10.1111\/j.1528-1157.1994.tb02930.x.","journal-title":"Epilepsia"},{"issue":"3","key":"3650_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3988\/jcn.2018.14.3.413","volume":"14","author":"Y Jang","year":"2018","unstructured":"Jang Y, Lee ST, Chu K, Lee SK. A psychiatric side effect of levetiracetam can mimic a relapse of anti-leucine-rich glioma inactivated 1 encephalitis. J Clin Neurol. 2018;14(3):413\u20134. https:\/\/doi.org\/10.3988\/jcn.2018.14.3.413.","journal-title":"J Clin Neurol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03650-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-022-03650-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-022-03650-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T01:05:29Z","timestamp":1667955929000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-022-03650-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3650"],"URL":"https:\/\/doi.org\/10.1186\/s13256-022-03650-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"20 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We submitted our manuscript with the code 99-1-101-48283 to the ethics committee of Tehran University Of Medical Sciences, and it was approved with the ethical code IR.TUMS.SINAHOSPITAL.REC.1399.005.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}